September 24–26, 2026
Cambridge, MA
Day(s)
:
Hour(s)
:
Minute(s)
:
Second(s)
The CMT Research Foundation unites the voices of patients, researchers, pharma companies, investors and regulatory agencies to develop treatments for CMT.
This event takes place over three days. Thursday and Friday are scientific meetings tailored toward investors, researchers and scientists working to better understand, and ultimately, end CMT. Saturday is primarily for patients and their families, providing a chance to interact with and inform the research community that is working so hard on their behalf. Attendees will have the opportunity to engage with others in the patient community, better understand their disease, and learn how they can participate in the latest research progress.
For the Scientific Community
September 24-25th
Two days for researchers, industry and government agencies to:
- EXPLORE cutting-edge and emerging research in CMT
- ADDRESS major barriers and opportunities in CMT drug development to accelerate progress
- ENGAGE with researchers, industry experts and patients to build momentum toward developing approved CMT treatments
For the Patient Community
September 26th
A day for the patient community to:
- LEARN about the latest developments and clinical trials in CMT
- INTERACT with distinguished scientific experts and clinicians
- ACT to speed treatments for patients and families
Sponsored by:
The Scientific Programming Committee
Bruce Carter, MD, PhD
Professor of Biochemistry and Associate Director of the Brain Institute
Vanderbilt University
Jenneen DeFiore
Vice President – Neuroscience
PPD part of Thermo Fisher Scientific
Yulia Grishchuk, PhD
Associate Director of Regulatory Affairs at the Gene and Cell Therapy Institute
Mass General Brigham
Marina Kennerson, PhD
Professor of Neurogenetics
ANZAC Research Institute and Sydney Medical School
Brett McCray, MD, PhD
Assistant Professor of Neurology
University of Michigan
Wolfgang Pernice, PhD
Assistant Professor of Neurological Sciences
Columbia University